INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

For the key trials, our articles and recipes, read the Gut Microbiome desk →

830 studies · page 26 of 35

2016 / Randomized crossover trial

Elevating colonic propionate decreased striatal anticipatory reward responses to high-energy foods and reduced ad libitum energy intake in healthy men.

Twenty healthy nonobese men completed an fMRI food picture evaluation task after consuming control inulin or inulin-propionate ester in a randomized crossover design. Increasing colonic propionate reduced the blood oxygen level-dependent signal in the caudate and nucleus accumbens, with the caudate reduction driven specifically by a decreased response to high-energy food. These effects were accompanied by lower subjective appeal of high-energy food pictures and reduced ad libitum energy intake, without changes in plasma PYY, GLP-1, glucose, or insulin.

Byrne CS, Chambers ES, Alhabeeb H, et al. Am J Clin Nutr, 2016. PMID 27169834

2016 / Randomized, double-blind crossover trial

Distal, but not proximal, colonic acetate infusions increased fasting fat oxidation and PYY in overweight or obese men.

Six overweight/obese men underwent two experimental periods with endoscopically placed catheters for distal and proximal colonic infusions of sodium acetate (100 or 180 mmol/l) or placebo across fasting and postprandial conditions. Distal colonic 180 mmol/l acetate infusions significantly increased fasting fat oxidation (1.78±0.28 vs. -0.78±0.89 g fat 2 h-1, P=0.015), fasting PYY (P=0.01), and postprandial glucose and insulin levels (P<0.05) compared to placebo. Distal 100 mmol/l acetate tended to decrease fasting TNF-α (P=0.067). In contrast, proximal colonic acetate infusions had no observed effects on substrate metabolism, circulating hormones, or inflammatory markers.

van der Beek CM, Canfora EE, Lenaerts K, et al. Clin Sci (Lond), 2016. PMID 27439969

2016 / Randomized controlled trial

Fig paste reduced colon transit time and improved symptoms in functional constipation.

A randomized, double-blind, placebo-controlled trial evaluated 8 weeks of Ficus carica paste versus placebo in 80 Korean participants with functional constipation. Supplementation significantly decreased colon transit time compared with placebo. Fig paste also significantly improved stool consistency and abdominal discomfort, while organ toxicity markers and blood parameters remained within normal ranges.

Baek HI, Ha KC, Kim HM, et al. Asia Pac J Clin Nutr, 2016. PMID 27440682

2016 / Randomized controlled crossover study and in vitro fermentations

Inulin-propionate ester (IPE-27) significantly reduced ad libitum energy intake compared with inulin control and IPE-54 in a crossover trial.

Researchers developed inulin short-chain fatty acid esters to deliver propionate directly to the colon and tested them in vitro and in humans. In a randomized controlled crossover study, participants received 10 g/day of IPE-27, IPE-54, or inulin control for 7 days. In vivo, IPE-27 produced greater 13C recovery in breath CO2 than IPE-54 (64.9 vs. 24.9%, P = 0.001) and reduced energy intake during an ad libitum test meal compared with inulin (439.5 vs. 703.9 kcal, P = 0.025) and IPE-54 (439.5 vs. 659.3 kcal, P = 0.025). Intake with IPE-54 did not differ significantly from inulin control.

Polyviou T, MacDougall K, Chambers ES, et al. Aliment Pharmacol Ther, 2016. PMID 27464984

2016 / Randomized, double-blind, placebo-controlled pilot study

Resveratrol supplementation significantly reduced disease activity and improved oxidative stress markers in patients with active ulcerative colitis.

Fifty-six patients with active mild to moderate ulcerative colitis were randomized to receive either 500 mg/day resveratrol capsules or placebo for 6 weeks. In the resveratrol group, serum SOD increased from 122.28 ± 11.55 to 125.77 ± 10.97, TAC increased from 9.87 ± 1.51 to 11.97 ± 1.61, and serum MDA decreased from 5.62 ± 1.18 to 3.42 ± 1.01 (p < 0.001). In addition, resveratrol supplementation significantly decreased disease activity and improved quality of life compared to baseline (p < 0.001).

Samsamikor M, Daryani NE, Asl PR, et al. Arch Med Res, 2016. PMID 27664491

2016 / Randomized controlled trial

Adding navy bean powder or rice bran was feasible, well tolerated, and significantly increased dietary fiber intake in colorectal cancer survivors.

Twenty-nine colorectal cancer survivors completed a randomized controlled trial receiving foods with cooked navy bean powder (35 g/day), heat-stabilized rice bran (30 g/day), or no added ingredient. The consumed amounts represented 4-9% of daily caloric intake, with no major gastrointestinal issues reported. Dietary fiber significantly increased in both the navy bean and rice bran groups at Weeks 2 and 4 compared with baseline and control (P <= 0.01). Telomere length correlated with age and HDL cholesterol at baseline, and with improved serum amyloid A levels at Week 4 (P <= 0.05).

Borresen EC, Brown DG, Harbison G, et al. Nutr Cancer, 2016. PMID 27689688

2016 / Animal experiments and 3-month human intervention trial

Dietary thylakoid supplementation increased total gut bacteria and Bacteroides fragilis in humans without causing steatorrhea.

This study evaluated green-plant thylakoids on gastrointestinal passage in rats and on gut microbiota and fecal fat in 34 healthy human volunteers receiving thylakoid or placebo treatments for three months. In rats, thylakoids reduced gastric emptying and intestinal transit acutely, with non-significant reductions after two weeks. In the human trial, thylakoids increased total bacteria and specifically the Bacteroides fragilis group compared to placebo, while failing to cause steatorrhea.

Stenblom EL, Weström B, Linninge C, et al. Nutr Metab (Lond), 2016. PMID 27777602

2015 / Randomized controlled trial

Gluten and dairy exposure did not alter intestinal permeability or behavior in autistic children.

A 4-week randomized, double-blind, placebo-controlled trial assessed the effects of gluten and milk on gut permeability and behavior in children with autism spectrum disorders. Intestinal permeability was evaluated using the lactulose:mannitol ratio, alongside standardized behavioral scores and gastrointestinal symptoms. Neither intestinal permeability nor behavioral metrics differed between groups receiving gluten and dairy versus placebo, and observed variations were small and not clinically meaningful.

Navarro F, Pearson DA, Fatheree N, et al. Nutr Neurosci, 2015. PMID 24564346

2015 / Randomized controlled trial

Burping did not reduce infant colic and significantly increased regurgitation episodes.

A randomized controlled trial compared routine burping to non-burping in 71 mother-infant pairs followed for 3 months. Colic episodes did not decrease significantly in burped infants compared with controls (adjusted RR 0.64; 95% CI, 0.22-1.86, p = 0.41; difference 1.57 episodes/infant/100 weeks [95% CI, -0.63 to 3.76]). Conversely, burping significantly increased regurgitation (adjusted RR 2.05; 95% CI, 1.92-2.18, p < 0.0001; difference 4.36 episodes/infant/week [95% CI, 4.04-4.69]).

Kaur R, Bharti B, Saini SK Child Care Health Dev, 2015. PMID 24910161

2015 / Randomized, single-blind, crossover trial

Ileal infusion of sucrose, casein, and safflower oil significantly reduced subsequent food intake compared with control in healthy adults.

Thirteen healthy participants received 90-minute ileal infusions of saline control, safflower oil (51.7 kcal), low-dose casein (17.2 kcal), high-dose casein (51.7 kcal), low-dose sucrose (17.2 kcal), or high-dose sucrose (51.7 kcal) via a naso-ileal catheter. Infusion of high-dose lipid, protein, and carbohydrate significantly reduced ad libitum food intake versus control (safflower oil: 464.3±90.7 kcal, P<0.001; high-dose casein: 458.0±78.6 kcal, P<0.005; high-dose sucrose: 399.0±57.0 kcal, P<0.0001 vs control: 586.7±70.2 kcal), an effect that persisted after adding infused calories. Secretion of cholecystokinin and peptide YY increased, while glucagon-like peptide-1 (7-36) did not; delays in gastric emptying and intestinal transit were observed across all macronutrients but were not statistically significant versus control.

van Avesaat M, Troost FJ, Ripken D, et al. Int J Obes (Lond), 2015. PMID 24957485

2015 / In vitro study, acute randomized crossover trial, and 24-week RCT

Targeted delivery of propionate to the colon stimulated gut hormones, reduced energy intake, and prevented weight gain in overweight adults.

Researchers tested the effects of an inulin-propionate ester using in vitro human colonic cells, an acute randomized controlled crossover trial, and a 24-week randomized controlled study in 60 overweight adults. Acute ingestion of 10 g inulin-propionate ester significantly increased postprandial plasma PYY and GLP-1 and reduced energy intake. Over 24 weeks, supplementation with 10 g/day significantly reduced weight gain, intra-abdominal adipose tissue distribution, and intrahepatocellular lipid content, while preventing the deterioration in insulin sensitivity observed with the inulin control.

Chambers ES, Viardot A, Psichas A, et al. Gut, 2015. PMID 25500202

2015 / Randomized controlled trial

Zinc in oral rehydration solution improved gut permeability but not clinical recovery from gastroenteritis.

Hospitalized children with gastroenteritis received rice-based oral rehydration solution with or without 3 mg zinc for 5 days. Both the zinc and control groups showed improvements in sucrose breath tests from baseline to day 5 (P < .05). Intestinal permeability measured by lactulose/rhamnose ratio significantly improved only in the zinc-fortified group (53.0 to 17.7, P < .05), though short-term recovery was not enhanced.

Tran CD, Hawkes J, Graham RD, et al. Clin Pediatr (Phila), 2015. PMID 25520366

2015 / In vivo human volunteer challenge and in vitro study

Very little titanium dioxide is absorbed gastrointestinally in humans after oral challenge, with no difference across three particle sizes.

Researchers conducted human in vivo and in vitro studies to evaluate the gastrointestinal absorption of titanium dioxide nanoparticles compared with larger particles. Human volunteer studies showed that very little titanium dioxide is absorbed gastrointestinally following an oral challenge, with no demonstrable difference in absorption across the three particle sizes tested. In vitro tests showed that all formulations agglomerated in simulated gastric fluid and when dispersed in polymeric or elemental foods, with virtually no translocation across the cell layer. The study found no evidence that nanoparticulate titanium dioxide is more likely to be absorbed in the gut than micron-sized particles.

Jones K, Morton J, Smith I, et al. Toxicol Lett, 2015. PMID 25597860

2015 / Randomized crossover trial

Ascorbic acid increased intestinal permeability and did not prevent aspirin-induced gut changes

In a crossover trial of 28 healthy female volunteers, 500 mg ascorbic acid alone augmented 6-hour lactulose excretion more than 600 mg aspirin alone compared to placebo. Administering both together produced an additive increase in lactulose excretion. In an additional test of 19 women, the timing of ascorbic acid administration before or after aspirin had no significant effect on sugar excretion.

Sequeira IR, Kruger MC, Hurst RD, et al. Basic Clin Pharmacol Toxicol, 2015. PMID 25641731

2015 / Randomized, double-blind, crossover trial

Small amounts of gluten worsened symptoms in adults with suspected nonceliac gluten sensitivity

A randomized, double-blind crossover trial evaluated 4.375 g/day gluten versus rice starch placebo for one week in 61 adults without celiac disease or wheat allergy. In 59 completing participants, gluten significantly increased overall symptoms compared with placebo (P = .034). Gluten provoked significantly more severe abdominal bloating (P = .040), abdominal pain (P = .047), foggy mind (P = .019), depression (P = .020), and aphthous stomatitis (P = .025).

Di Sabatino A, Volta U, Salvatore C, et al. Clin Gastroenterol Hepatol, 2015. PMID 25701700

2015 / Multicenter randomized, placebo-controlled, double-blind trial

Adding curcumin to mesalamine therapy induced higher rates of clinical and endoscopic remission in patients with mild-to-moderate active ulcerative colitis.

Fifty patients with active mild-to-moderate ulcerative colitis unresponsive to maximum mesalamine therapy were randomized to receive curcumin capsules (3 g/day, n = 26) or identical placebo (n = 24) for 1 month alongside mesalamine. In the intention-to-treat analysis, 53.8% (14/26) of patients in the curcumin group achieved clinical remission at week 4 compared with 0% (0/24) in the placebo group (P = .01; OR, 42; 95% CI, 2.3-760). Clinical response occurred in 65.3% of the curcumin group vs. 12.5% in the placebo group (P < .001). Endoscopic remission was observed in 38% (8/22) evaluated in the curcumin group vs. 0% (0/16) in the placebo group (P = .043). Adverse events were rare and comparable between groups.

Lang A, Salomon N, Wu JC, et al. Clin Gastroenterol Hepatol, 2015. PMID 25724700

2015 / Multicenter, double-blind, randomized crossover trial

In children aged 4–6 years, single doses of erythritol up to 15 g were well tolerated, with diarrhea or severe symptoms observed at 20 g and 25 g.

A multicenter trial examined the gastrointestinal tolerance of a single oral dose of erythritol (5, 15, 20, or 25 g) versus an isosweet sucrose placebo in a 250-ml beverage consumed between meals by children aged 4-6 years. Statistically significantly more episodes of diarrhea and/or severe GI symptoms occurred in the 20 and 25 g groups compared with placebo, but not in the 5 and 15 g groups. Stool consistency on the Bristol stool scale was lower in the 15, 20, and 25 g groups during the first 24 hours, while nausea, vomiting, borborygmi, excess flatus, and abdominal pain did not differ significantly from placebo at any dose. The researchers concluded that up to 15 g (0.73 g/kg body weight) was well tolerated, serving as the no observed effect level for diarrhea or severe GI symptoms.

Jacqz-Aigrain E, Kassai B, Cornu C, et al. Eur J Clin Nutr, 2015. PMID 25744158

2015 / Clinical study with intervention and case-control components

A bowel stimulation regimen of high fiber, fluid, exercise, and a prokinetic reduced colon transit time, fecal load, and abdominal symptoms.

Studies examined whether fecal retention contributes to functional bowel disorders, appendicitis, and hemorrhoids. Patients with functional bowel disorders had significantly increased colon transit time (CTT) and fecal load compared to controls. An intervention combining a fiber-rich diet, fluid, physical activity, and a prokinetic drug significantly reduced CTT, fecal load, bloating, and abdominal pain, while improving defecation patterns. Surgical interventions (colectomy, stapled hemorrhoidopexy) were evaluated in refractory constipation and hemorrhoid cohorts.

Raahave D Dan Med J, 2015. PMID 25748875

2015 / Randomized controlled trial

Daily shiitake mushroom consumption improved markers of immune function in healthy young adults.

Fifty-two healthy adults consumed 5 g or 10 g of dried shiitake mushrooms daily for 4 weeks in a parallel-group trial. Mushroom intake increased ex vivo proliferation of γδ-T cells by 60% and natural killer T cells twofold (both p < 0.0001), along with greater activation receptor expression. Salivary secretory immunoglobulin A increased and serum C-reactive protein decreased, accompanied by distinct shifts in cytokine secretion profiles.

Dai X, Stanilka JM, Rowe CA, et al. J Am Coll Nutr, 2015. PMID 25866155

2015 / Two-week dietary exchange trial

A 2-week diet swap between African Americans and rural Africans led to reciprocal changes in mucosal cancer biomarkers, microbiota, and metabolome markers.

Researchers performed supervised 2-week food exchanges where African Americans consumed a high-fibre, low-fat African-style diet and rural Africans consumed a high-fat, low-fibre western-style diet. Compared with usual diets, the dietary switch led to reciprocal changes in mucosal biomarkers of cancer risk, microbiota, and the metabolome. In African Americans, these changes were highlighted by increased saccharolytic fermentation and butyrogenesis alongside suppressed secondary bile acid synthesis.

O'Keefe SJ, Li JV, Lahti L, et al. Nat Commun, 2015. PMID 25919227

2015 / Intervention trial with periodic fecal sampling

A gut microbiota-targeted dietary intervention altered fecal menaquinones, which were linked to specific bacterial taxa but not cardiometabolic markers.

Researchers evaluated fecal menaquinone profiles, gut microbiota structure, and cardiometabolic biomarkers in 77 overweight Chinese adults consuming a prescribed diet designed to alter gut microbiota composition. Covariance among fecal menaquinones identified two distinct groups ('menaquinotypes'), characterized by differences in MK5, MK9-MK13, and relative abundance of species mostly within Prevotella and Bacteroides. During the intervention, fecal MK4, MK6, and MK8 decreased (P < 0.05), and longitudinal shifts in >100 operational taxonomic units related to altered individual menaquinones. However, neither individual menaquinones nor menaquinotypes were longitudinally associated with markers of glycemia, insulin resistance, or inflammation.

Karl JP, Fu X, Wang X, et al. Am J Clin Nutr, 2015. PMID 26016865

2015 / Randomized crossover trial

Butyrylated high-amylose maize starch prevented red meat-induced increases in rectal O6MeG adducts in healthy humans.

In a randomized crossover trial, 23 healthy individuals consumed 300 g/d of cooked red meat alone (HRM) or with 40 g/d of butyrylated high-amylose maize starch (HRM+HAMSB) for 4 weeks each, separated by a 4-week washout. The HRM diet increased rectal O6MeG adducts by 21% relative to baseline (P < 0.01), but the addition of HAMSB prevented this increase. Epithelial proliferation increased with both diets compared to baseline, but was lower following HRM+HAMSB compared to HRM (P < 0.05). HRM+HAMSB also increased stool SCFA excretion by over 20% (P < 0.05) and altered fecal microbiota abundances.

Le Leu RK, Winter JM, Christophersen CT, et al. Br J Nutr, 2015. PMID 26084032

2015 / Double-blind randomised placebo-controlled study

In Crohn's disease patients in remission, 2000 IU/day vitamin D for 3 months maintained intestinal permeability and increased cathelicidin levels.

Twenty-seven Crohn's disease patients in remission were assigned to 2000 IU/day vitamin D or placebo for 3 months. At 3 months, 25(OH)D levels were significantly higher in the treated group (p < 0.001), with increased LL-37 concentrations (p = 0.050) and maintenance of intestinal permeability, whereas placebo patients experienced increases in small bowel (p = 0.018) and gastro-duodenal permeability (p = 0.030). Patients reaching 25(OH)D ≥ 75 nmol/L at 3 months had significantly lower CRP (p = 0.019), higher Quality of Life (p = 0.037), and higher LL-37 concentrations (p < 0.001) compared to those with levels < 75 nmol/L.

Raftery T, Martineau AR, Greiller CL, et al. United European Gastroenterol J, 2015. PMID 26137304

2015 / Randomized controlled trial

Lactobacillus casei Shirota did not significantly alter TMAO in metabolic syndrome patients.

In an open-label randomized trial, 30 participants with metabolic syndrome were assigned to consume Lactobacillus casei Shirota three times daily (6.5 × 10^9 CFU) or standard care for 12 weeks; 28 completed the protocol. Plasma TMAO concentrations declined in both the probiotic group (4.66 ± 2.66 to 4.31 ± 2.04 μM) and controls (4.64 ± 2.75 to 4.40 ± 2.14 μM). The net changes (-0.25 ± 2.39 vs. -0.34 ± 2.23 μM) did not differ significantly between arms (p = 0.510).

Tripolt NJ, Leber B, Triebl A, et al. Atherosclerosis, 2015. PMID 26188537